
Aurobindo Pharma frontrunner to secure $5.6bn deal for Advent’s Zentiva
India’s Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generics manufacturer Zentiva from Advent International in a deal valued at up to $5.5bn, in what would be one of the largest European healthcare exits of the year, according to a report by the Economic Times.